NightHawk Biosciences, a CDMO, announced its Scorpius BioManufacturing subsidiary has been awarded a multimillion-dollar contract to provide process development, analytical, and cGMP manufacturing services for a publicly traded biotech company’s Phase 2 clinical program.
 

Jeff Wolf, CEO of NightHawk Biosciences, said, “We are proud to have been selected to help advance this potentially lifesaving therapy through the clinic. Scorpius has multiple clients with Orphan Drug Designations from the FDA, and our San Antonio facility is especially well-suited to advance these important programs. This new client, needing biologic manufacturing for a Phase 2 clinical program under cGMP guidelines, will benefit from Scorpius’ comprehensive services in process development, bioanalysis, and manufacturing. The client, transitioning from a large CDMO, chose Scorpius to assist in this Phase 2 program based on our adaptability, dedicated service, and commitment to meeting project timelines. The scope of work, which includes producing a monoclonal antibody (mAb) in Scorpius’ mammalian facility, is expected to be completed in 2024. We are extremely pleased with the success and traction Scorpius gained in 2023, our first full year in operation, and we are excited to see this momentum continue as we witness rising demand for our mammalian and microbial biomanufacturing services.”